LENSAR Sets Dec. 18 Virtual Annual Meeting; Director Elections, Auditor Ratification on Docket

TL;DR

**LENSAR's upcoming annual meeting is a routine governance check, but keep an eye on that Alcon merger mention – it's the real game-changer for LNSR.**

AI Summary

LENSAR, Inc. (LNSR) has filed a DEF 14A proxy statement on November 5, 2025, for its annual meeting on December 18, 2025. The primary proposals include the election of three Class II directors—Nicholas T. Curtis, Todd B. Hammer, and Aimee S. Weisner—to serve until the 2028 annual meeting, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025. The filing indicates that as of the October 24, 2025 record date, there were 11,944,546 shares of common stock and 20,000 shares of Series A Convertible Preferred Stock outstanding and entitled to vote. The company emphasizes the importance of stockholder participation, offering virtual attendance and voting options via www.virtualshareholdermeeting.com/LNSR2025. While specific revenue and net income figures are not detailed in this proxy statement, the focus is on corporate governance and the upcoming director elections and auditor ratification. A notable mention is the potential impact of a contemplated merger with Alcon Research, LLC, which could affect the Annual Meeting's proceedings.

Why It Matters

This DEF 14A filing outlines LENSAR's critical governance decisions, directly impacting investor confidence and strategic direction. The election of Class II directors, including CEO Nicholas T. Curtis, shapes the company's leadership for the next three years, influencing future operational and financial performance. Ratifying PricewaterhouseCoopers LLP ensures continued financial transparency and regulatory compliance, crucial for maintaining market trust. The mention of a potential merger with Alcon Research, LLC introduces a significant competitive context, suggesting a strategic shift that could redefine LENSAR's market position and offer new opportunities or challenges for employees and customers in the ophthalmic technology sector.

Risk Assessment

Risk Level: low — The risk level is low as this DEF 14A primarily covers routine corporate governance matters: director elections and auditor ratification. There are no immediate red flags regarding financial distress or significant operational changes, though the mention of a potential merger with Alcon Research, LLC introduces a future, currently undefined, risk or opportunity.

Analyst Insight

Investors should vote on the director nominees and auditor ratification as recommended by the Board to support stable governance. Pay close attention to any future announcements regarding the contemplated merger with Alcon Research, LLC, as this could be a material event impacting LNSR's valuation and strategic trajectory.

Key Numbers

• 11,944,546 — Shares of common stock outstanding (Entitled to vote as of October 24, 2025)
• 20,000 — Shares of Series A Convertible Preferred Stock outstanding (Entitled to vote as of October 24, 2025)
• 2025-11-05 — Filing Date (Date DEF 14A was filed)
• 2025-12-18 — Annual Meeting Date (Date of the virtual annual meeting)
• 11:00 a.m. — Annual Meeting Time (Eastern Time for the virtual annual meeting)
• 2025-10-24 — Record Date (Stockholders of record entitled to vote)
• 2028 — Director Term Expiration (Year Class II directors' terms expire)

Key Players & Entities

• LENSAR, Inc. (company) — Registrant and issuer of proxy statement
• William J. Link, PhD (person) — Chairman of the Board
• Nicholas T. Curtis (person) — Chief Executive Officer and Class II director nominee
• Todd B. Hammer (person) — Class II director nominee
• Aimee S. Weisner (person) — Class II director nominee
• PricewaterhouseCoopers LLP (company) — Independent registered public accounting firm for 2025
• Securities and Exchange Commission (regulator) — Regulatory body for proxy filings
• Alcon Research, LLC (company) — Contemplated merger partner
• Alan B. Connaughton (person) — Named Executive Officer
• Thomas R. Staab, II (person) — Named Executive Officer

FAQ

Industry Context

LENSAR operates in the ophthalmic surgical device market, specifically focusing on femtosecond laser technology for cataract surgery. This sector is characterized by technological innovation, competition from established players and emerging companies, and a focus on improving surgical outcomes and patient recovery. The market is influenced by healthcare reimbursement policies, physician adoption rates, and the overall demand for elective surgical procedures.

Regulatory Implications

As a medical device company, LENSAR is subject to stringent regulatory oversight by bodies like the U.S. Food and Drug Administration (FDA) regarding product safety and efficacy. Changes in healthcare regulations, reimbursement policies, or compliance requirements could impact the company's operations and market access. The potential merger with Alcon could also trigger regulatory reviews and approvals.

What Investors Should Do

1. Review the director nominees (Nicholas T. Curtis, Todd B. Hammer, Aimee S. Weisner) and vote for or against their election to ensure alignment with the company's strategic direction and governance standards.
2. Vote to ratify PricewaterhouseCoopers LLP as the independent auditor to maintain financial transparency and confidence in the company's financial reporting.
3. Monitor developments regarding the contemplated merger with Alcon Research, LLC, as this significant event could materially impact LENSAR's future as an independent entity and shareholder value.
4. Ensure voting rights are exercised by the record date of October 24, 2025, by participating in the virtual meeting or submitting a proxy, given the 11,944,546 shares of common stock and 20,000 shares of Series A Convertible Preferred Stock entitled to vote.

Key Dates

• 2025-11-05: Distribution of Proxy Statement — Informs shareholders about the annual meeting agenda, director nominations, and auditor ratification, enabling informed voting.
• 2025-10-24: Record Date — Determines which shareholders are eligible to vote at the annual meeting.
• 2025-12-18: Annual Meeting of Stockholders — Key date for voting on director elections and auditor ratification, and potentially discussing company matters like the Alcon merger.
• 2028: Director Term Expiration — Indicates the end of the term for the elected Class II directors, setting the stage for future board composition decisions.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information about a company's annual meeting, including director nominations, executive compensation, and other corporate governance matters. (This is the primary document for understanding the agenda and key proposals for LENSAR's annual meeting.)

Proxy Statement

A document that a company's management sends to shareholders before a shareholder meeting to solicit votes. (This document outlines the proposals to be voted on, including director elections and auditor ratification.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive dividends, vote at a shareholder meeting, or exercise other rights. (Establishes the pool of shareholders entitled to vote on the proposals at the December 18, 2025 meeting.)

Class II Directors

In a classified board structure, directors are divided into classes (e.g., Class I, II, III), with each class elected for a staggered three-year term. Class II directors are those up for election in the current cycle. (The election of these three Class II directors is a primary agenda item for the annual meeting.)

Series A Convertible Preferred Stock

A class of preferred stock that can be converted into a specified number of shares of common stock. (These shares are outstanding and entitled to vote, representing a portion of the voting power at the meeting.)

Year-Over-Year Comparison

This DEF 14A filing focuses on the upcoming 2025 annual meeting, with the record date for voting set as October 24, 2025. Specific financial performance metrics for the preceding year (2024) are not detailed within this proxy statement, which primarily addresses corporate governance, director elections, and auditor ratification. Therefore, a direct comparison of revenue growth, margin changes, or new risks against a prior filing's financial highlights is not feasible based solely on this document.

Filing Documents

• lnsr-proxy-2025.htm (DEF 14A) — 1136KB
• img37589740_0.jpg (GRAPHIC) — 62KB
• img37589740_1.jpg (GRAPHIC) — 62KB
• img37589740_2.jpg (GRAPHIC) — 62KB
• img37589740_3.jpg (GRAPHIC) — 427KB
• img37589740_4.jpg (GRAPHIC) — 189KB
• 0001193125-25-265686.txt ( ) — 2228KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 31 Delinquent Section 16(a) Reports 33 CERTAIN TRANSACTIONS WITH RELATED PERSONS 34 Policies and Procedures on Transactions with Related Persons 34 North Run Investment 34 Indemnification Agreements 34 STOCKHOLDER PROPOSALS AND DIRECTOR NOMINATIONS 36 HOUSEHOLDING 36 2024 ANNUAL REPORT 37 ii LENSAR, Inc. 2800 Discovery Drive Orlando, Florida 32826 PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 18, 2025 This proxy statement (the “Proxy Statement”) and our annual report for the fiscal year ended December 31, 2024 (the “Annual Report” and, together with this Proxy Statement, the “proxy materials”) are being furnished by and on behalf of the board of directors (the “Board” or “Board of Directors”) of LENSAR, Inc. (the “Company,” “LENSAR,” “we,” “us,” or “our”), in connection with our 2025 annual meeting of stockholders (the “Annual Meeting”). The Notice of Annual Meeting and this Proxy Statement are first being distributed or made available, as the case may be, on or about November 5, 2025. GENERAL INFORMATION ABOUT TH E ANNUAL MEETING AND VOTING When and where will the Annual Meeting be held? The Annual Meeting will be held on Thursday, December 18, 2025 at 11:00 a.m., Eastern Time. The Annual Meeting will be a completely virtual meeting, which will be conducted via live webcast. You will be able to attend the Annual Meeting online and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/LNSR2025 and entering your 16-digit control number included in your Notice of Internet Availability of Proxy Materials, on your proxy card or on the instructions that accompanied your proxy materials. If you lose your 16-digit control number, you may joi

View Full Filing

View this DEF 14A filing on SEC EDGAR